{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:19:10Z","timestamp":1777997950209,"version":"3.51.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515010260"],"award-info":[{"award-number":["2020A1515010260"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pyrimidine metabolism is a hallmark of cancer and will soon become an essential part of cancer therapy. In the tumor microenvironment, cells reprogram pyrimidine metabolism intrinsically and extracellularly, thereby promoting tumorigenesis. Metabolites in pyrimidine metabolism have a significant impact on promoting cancer advancement and modulating immune system responses. In preclinical studies and practical clinical applications, critical targets in pyrimidine metabolism are acted upon by drugs to exert promising therapeutic effects on tumors. However, the pyrimidine metabolism in breast cancer (BC) is still largely underexplored. In this study, 163 credible pyrimidine metabolism-related genes (PMGs) were retrieved, and their somatic mutations and expression levels were determined. In addition, by using The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) databases, 12 PMGs related to the overall survival (OS) were determined using the univariate Cox regression analysis. Subsequently, by performing the LASSO Cox hazards regression analysis in the 12 PMGs in TCGA-BRCA dataset, we developed a prognosis nomogram using eight OS-related PMGs and then verified the same in the METABRIC, GSE96058, GSE20685, GSE42568 and GSE86166 data. Moreover, we validated relationships between the pyrimidine metabolism index (PMI) and the survival probability of patients, essential clinical parameters, including the TNM stage and the PAM50 subtypes. Next, we verified the predictive capability of the optimum model, including the signature, the PAM50 subtype, and age, using ROC analysis and calibration curve, and compared it with other single clinical factors for the predictive power of benefit using decision curve analysis. Finally, we investigated the potential effects of pyrimidine metabolism on immune checkpoints, tumor-infiltrating immune cells, and cytokine levels and determined the potential implications of pyrimidine metabolism in BC immunotherapy. In conclusion, our findings suggest that pyrimidine metabolism has underlying prognostic significance in BC and can facilitate a new management approach for patients with different prognoses and more precise immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1056680","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:37:53Z","timestamp":1669711073000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature"],"prefix":"10.3389","volume":"13","author":[{"given":"Yongzhou","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinpei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongfang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.09.001","article-title":"Breast cancer: Multiple subtypes within a tumor","volume":"3","author":"Yeo","year":"2017","journal-title":"Trends Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature08987","article-title":"International network of cancer genome projects","volume":"464","author":"Hudson","year":"2010","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.843515","article-title":"Prognosis and dissection of immunosuppressive microenvironment in breast cancer based on fatty acid metabolism-related signature","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0123-5","article-title":"Metabolic regulation of cell growth and proliferation","volume":"20","author":"Zhu","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau4972","article-title":"Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells","volume":"11","author":"Wang","year":"2019","journal-title":"Sci Trans Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia."},{"key":"B9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cmet.2018.10.014","article-title":"Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells","volume":"29","author":"Bajzikova","year":"2019","journal-title":"Cell Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1225-4","article-title":"MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism","volume":"39","author":"Olou","year":"2020","journal-title":"Oncogene."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.molmet.2020.02.005","article-title":"A non-proliferative role of pyrimidine metabolism in cancer","volume":"35","author":"Siddiqui","year":"2020","journal-title":"Mol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature."},{"key":"B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","article-title":"Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism","volume":"3","author":"Elia","year":"2021","journal-title":"Nat Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2020.02.005","article-title":"Nitrogen metabolism in cancer and immunity","volume":"30","author":"Kurmi","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer","volume":"79","author":"Gaynor","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.718863","article-title":"Mitochondrial-linked De novo pyrimidine biosynthesis dictates human T-cell proliferation but not expression of effector molecules","volume":"12","author":"Peeters","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60473","article-title":"Inhibition of de novo pyrimidine synthesis augments gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer","volume":"17","author":"Phan","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation","volume":"40","author":"McCarthy","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/1471-2105-14-244","article-title":"RCircos: an r package for circos 2D track plots","volume":"14","author":"Zhang","year":"2013","journal-title":"BMC Bioinf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.834593","article-title":"Establishment of a cell necroptosis index to predict prognosis and drug sensitivity for patients with triple-negative breast cancer","volume":"9","author":"Xie","year":"2022","journal-title":"Front Mol bioscie"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Software"},{"key":"B23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.21037\/atm.2017.04.01","article-title":"Drawing nomograms with r: applications to categorical outcome and survival data","volume":"5","author":"Zhang","year":"2017","journal-title":"Ann Trans Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models: Users' guides to the medical literature","volume":"318","author":"Alba","year":"2017","journal-title":"Jama."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106936","article-title":"Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery","volume":"106936","author":"Zou","year":"2022","journal-title":"Int J Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1022147","article-title":"Turning up a new pattern: Identification of cancer-associated fibroblast-related clusters in TNBC","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.874731","article-title":"Integrative dissection of novel lactate metabolism-related signature in the tumor immune microenvironment and prognostic prediction in breast cancer","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1877","article-title":"Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer","volume":"29","author":"Hernandez-Aya","year":"2011","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10732748221099230","DOI":"10.1177\/10732748221099230","article-title":"Therapeutic landscape of human epidermal growth factor receptor 2-positive breast cancer","volume":"29","author":"Xie","year":"2022","journal-title":"Cancer control J Moffitt Cancer Center"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.07.003","article-title":"Pyrimidine pathways in health and disease","volume":"11","author":"L\u00f6ffler","year":"2005","journal-title":"Trends Mol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.10.012","article-title":"Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer","volume":"195","author":"Madak","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R400007200","article-title":"Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway","volume":"279","author":"Evans","year":"2004","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2017.07.005","article-title":"Targeting the selenoprotein thioredoxin reductase 1 for anticancer therapy","volume":"136","author":"Arn\u00e9r","year":"2017","journal-title":"Adv Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf7444","article-title":"Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy","volume":"10","author":"Stafford","year":"2018","journal-title":"Sci Trans Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"19084","DOI":"10.1038\/s41598-019-55641-6","article-title":"Plasma activity of thioredoxin reductase as a novel biomarker in gastric cancer","volume":"9","author":"Peng","year":"2019","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1038\/s41598-018-38153-7","article-title":"Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: a Large-scale, multicenter study","volume":"9","author":"Ye","year":"2019","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: Facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3743-x","article-title":"Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer","volume":"156","author":"Matsumoto","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"St\u00fcber","year":"2020","journal-title":"J immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell."},{"key":"B45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat Rev Canc"},{"key":"B46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.semcancer.2019.12.018","article-title":"The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies","volume":"72","author":"Baxevanis","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1056680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:37:57Z","timestamp":1669711077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1056680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2022.1056680"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1056680","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1056680"}}